An emerging generic drug player committed to providing access to affordable medicines.

Beximco Pharma

Beximco Pharmaceuticals Ltd.

Beximco Pharmaceuticals Ltd (Beximco Pharma) is an emerging generic drug player committed to providing access to affordable medicines. Company’s state-of-the-art manufacturing facilities have been accredited by the regulatory authorities of Australia, European Union, Canada, and Brazil, among others, and it currently focuses on building presence in many emerging and developed markets around the world.

Beximco Pharma is consistently building upon its portfolio and currently producing more than 500 products encompassing broad therapeutic categories and the Company has created strong differentiation by offering a range of high-tech, specialized products which are difficult to imitate.

Requirements: Medical Promotion Executive
Walk-In Interview: Rangpur, Rajshahi, Bogura, Dhaka

Beximco Pharma COO attends WHO’s 2nd World Production Forum.

Beximco Pharma Chief Operating Officer Rabbur Reza participated as a key panelists in the Second World Local Production Forum (WLPF) being held in Hague, Netherlands during 6-8 November, 2023. The World Local Production Forum is an initiative of WHO with the aim of increasing access to medicines and other health technologies. Mr Reza discussed on the evolution of Bangladesh pharma industry and the importance and challenges of achieving sustainable local manufacturing.

Beximco Pharma team led by COO Mr. Rabbur Reza have attended the largest expo on pharmaceuticals, CPhI Worldwide, being held in Barcelona, Spain during 24-26 October 2023

Congratulations to our Quality Circle team on their GOLD award !!!

Beximco Pharma on Forbes’ list of Best Companies in Asia

Beximco Pharma has made it to the list of the top 200 publicly listed companies in the Asia-Pacific region published by Forbes Magazine. 
Mr. Rabbur Reza, COO of the company, received the award in a grand ceremony held on November 21, 2023 in Manila, Philippines. 
The US based Forbes Magazine recently published its "Asia's 200 Best Under A Billion" list which spotlights 200 top-performing publicly listed companies in the Asia-Pacific region with annual sales under US$1 billion. From a universe of over 20,000 small and midsized companies in the region, these 200 Best Under A Billion companies have track records of exceptional corporate performance. This is the 3rd time Beximco Pharma has made it to this list.

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

Beximco Pharmaceuticals Limited

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 11, 2024 5:47 PM	18aa8256
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b19d0c8d
crunchbase profile	general	Nov 27, 2024 2:36 PM	51c38839
li profile	general	Jul 11, 2024 5:47 PM	101f1fb3
translate crunchbase fundingrounds	general
peers	general	Jul 11, 2024 5:47 PM	b4a2eeec
news basic	general	Jul 11, 2024 5:47 PM	200c08b2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BEXIMCOPHARMA

Beximco Pharma

Last Close

33.50

22/11 14:00

Market Cap

1.73M

Beta: -

Volume Today

516.64K

Avg: -